Pub Date : 2025-12-12DOI: 10.1016/j.ijrobp.2025.08.064
David P. Horowitz MD, Lisa A. Kachnic MD, FASTRO
{"title":"Sequencing the InterAACTion Between Systemic and Local Treatments","authors":"David P. Horowitz MD, Lisa A. Kachnic MD, FASTRO","doi":"10.1016/j.ijrobp.2025.08.064","DOIUrl":"10.1016/j.ijrobp.2025.08.064","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 1","pages":"Pages 9-10"},"PeriodicalIF":6.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1016/j.ijrobp.2025.10.023
Arpit M. Chhabra MD, Bridget F. Koontz MD, FASTRO, Jordan Johnson MSHA, MLS, Mudit Chowdhary MD, Casey Chollet-Lipscomb MD, James E. Bates MD, Michael Weisman MD, Chirag Shah MD, Join Y. Luh MD
{"title":"In Reply to Starrs et al","authors":"Arpit M. Chhabra MD, Bridget F. Koontz MD, FASTRO, Jordan Johnson MSHA, MLS, Mudit Chowdhary MD, Casey Chollet-Lipscomb MD, James E. Bates MD, Michael Weisman MD, Chirag Shah MD, Join Y. Luh MD","doi":"10.1016/j.ijrobp.2025.10.023","DOIUrl":"10.1016/j.ijrobp.2025.10.023","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 1","pages":"Pages 227-228"},"PeriodicalIF":6.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1016/j.ijrobp.2025.11.060
Aurelia Alati, Kamel Debbi, Nathaniel Scher, Claire Meynard, Antoine Mavrikios, Florence Huguet, Hanene Boudabous, Jacques Medioni, Joseph Gligorov, Alexander Bennassi, Marc-Antoine Benderra, Jean-Philippe Spano, Elias Assaf, Alain Toledano, Laurent Quero, Cyrus Chargari, Catherine Durdux, Yazid Belkacemi
Purpose: Based on the results of the ASCENT trial, sacituzumab govitecan (SG) has been approved for the treatment of breast cancer. With the expanding indications across multiple cancers, data on its combination with radiation therapy (RT) are needed.
Methods and materials: ATTENTION is a retrospective multicenter study from 6 French institutions. Eligibility criteria included patients with breast cancer who received RT and SG between September 2021 and January 2025. Concomitant treatment was defined as RT administered within 4 days before or after SG administration. Data were collected through an online questionnaire and centralized after medical record review, and protocol validation by the local ethics committee. The primary endpoint was safety profiles according to the Common Terminology Criteria for Adverse Events, version 5.0. Secondary endpoints included treatment response, evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1 criteria and/or clinical symptom improvement. Assessment was performed 4-12 weeks after RT.
Results: Fifty-five patients (63 lesions) were included. The median age was 56 years (37-82). SG and RT were administered concurrently in 37 lesions (median, 3 days), sequentially in 26 lesions (median, 10 days). Subtypes included human epidermal growth factor receptor 2 (HER2)-/hormone receptors (HR)- (30%), HER2-/HR+ (27%), HER2-low/HR+ (24%), HER2-low/HR- (18%), and HER2+ (2%). SG was given as second-line in 16%, and ≥ fourth-line in 54%. RT was symptomatic in 57% and for progression in 43%, mostly targeting bone (49%) and brain (32%), using 3D conformal RT (52%), stereotactic body RT (40%), or intensity modulated RT (8%). With a median follow-up of 7.9 months (1.7-35.4), RT-related toxicities of grade 1-2 occurred in 17 cases (27%), (3 dermatitis, 4 esophagitis, and 1 brain radionecrosis). No grade ≥ 3 toxicity occurred with concomitant SG. The overall response rate was 25% complete and 80% partial responses. Median overall survival was 12.9 months (95% CI, 7.97-17.77).
Conclusions: ATTENTION is the largest study that confirms the feasibility and promising efficacy of concurrent treatment, pending confirmation in prospective trials.
{"title":"Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION Study.","authors":"Aurelia Alati, Kamel Debbi, Nathaniel Scher, Claire Meynard, Antoine Mavrikios, Florence Huguet, Hanene Boudabous, Jacques Medioni, Joseph Gligorov, Alexander Bennassi, Marc-Antoine Benderra, Jean-Philippe Spano, Elias Assaf, Alain Toledano, Laurent Quero, Cyrus Chargari, Catherine Durdux, Yazid Belkacemi","doi":"10.1016/j.ijrobp.2025.11.060","DOIUrl":"10.1016/j.ijrobp.2025.11.060","url":null,"abstract":"<p><strong>Purpose: </strong>Based on the results of the ASCENT trial, sacituzumab govitecan (SG) has been approved for the treatment of breast cancer. With the expanding indications across multiple cancers, data on its combination with radiation therapy (RT) are needed.</p><p><strong>Methods and materials: </strong>ATTENTION is a retrospective multicenter study from 6 French institutions. Eligibility criteria included patients with breast cancer who received RT and SG between September 2021 and January 2025. Concomitant treatment was defined as RT administered within 4 days before or after SG administration. Data were collected through an online questionnaire and centralized after medical record review, and protocol validation by the local ethics committee. The primary endpoint was safety profiles according to the Common Terminology Criteria for Adverse Events, version 5.0. Secondary endpoints included treatment response, evaluated according to Response Evaluation Criteria in Solid Tumors, version 1.1 criteria and/or clinical symptom improvement. Assessment was performed 4-12 weeks after RT.</p><p><strong>Results: </strong>Fifty-five patients (63 lesions) were included. The median age was 56 years (37-82). SG and RT were administered concurrently in 37 lesions (median, 3 days), sequentially in 26 lesions (median, 10 days). Subtypes included human epidermal growth factor receptor 2 (HER2)-/hormone receptors (HR)- (30%), HER2-/HR+ (27%), HER2-low/HR+ (24%), HER2-low/HR- (18%), and HER2+ (2%). SG was given as second-line in 16%, and ≥ fourth-line in 54%. RT was symptomatic in 57% and for progression in 43%, mostly targeting bone (49%) and brain (32%), using 3D conformal RT (52%), stereotactic body RT (40%), or intensity modulated RT (8%). With a median follow-up of 7.9 months (1.7-35.4), RT-related toxicities of grade 1-2 occurred in 17 cases (27%), (3 dermatitis, 4 esophagitis, and 1 brain radionecrosis). No grade ≥ 3 toxicity occurred with concomitant SG. The overall response rate was 25% complete and 80% partial responses. Median overall survival was 12.9 months (95% CI, 7.97-17.77).</p><p><strong>Conclusions: </strong>ATTENTION is the largest study that confirms the feasibility and promising efficacy of concurrent treatment, pending confirmation in prospective trials.</p>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":" ","pages":""},"PeriodicalIF":6.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1016/j.ijrobp.2025.09.014
Charles B. Simone II MD
{"title":"A Potential Path Toward Finally Improving Outcomes With Concurrent Immunotherapy and Chemoradiation for Lung Cancer: Low-Dose Radiation Therapy Lessons From the MATCH Trial in Extensive-Stage Small Cell Lung Cancer","authors":"Charles B. Simone II MD","doi":"10.1016/j.ijrobp.2025.09.014","DOIUrl":"10.1016/j.ijrobp.2025.09.014","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 1","pages":"Pages 174-176"},"PeriodicalIF":6.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1016/j.ijrobp.2025.08.020
Imaad Said BS , Musaddiq J. Awan MD , Stuart J. Wong MD , Abdullah A. Memon BS , Tyce Kearl MD, PhD , Peiman Hematti MD , Becky Massey MD , Jennifer Bruening MD , Kenneth Akakpo MD , Joseph Zenga MD , Heather A. Himburg PhD
{"title":"Radiation-Induced Loss of Tumor-Reactive T Cells Calls for More Rationally Designed Radioimmunotherapy Approaches","authors":"Imaad Said BS , Musaddiq J. Awan MD , Stuart J. Wong MD , Abdullah A. Memon BS , Tyce Kearl MD, PhD , Peiman Hematti MD , Becky Massey MD , Jennifer Bruening MD , Kenneth Akakpo MD , Joseph Zenga MD , Heather A. Himburg PhD","doi":"10.1016/j.ijrobp.2025.08.020","DOIUrl":"10.1016/j.ijrobp.2025.08.020","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 1","pages":"Pages 190-193"},"PeriodicalIF":6.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145718878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-12DOI: 10.1016/j.ijrobp.2025.08.022
Clifton David Fuller MD, PhD, Kristy K. Brock PhD, Katherine A. Hutcheson PhD, Stephen Y. Lai MD, PhD
{"title":"In Regard to Hanna et al.","authors":"Clifton David Fuller MD, PhD, Kristy K. Brock PhD, Katherine A. Hutcheson PhD, Stephen Y. Lai MD, PhD","doi":"10.1016/j.ijrobp.2025.08.022","DOIUrl":"10.1016/j.ijrobp.2025.08.022","url":null,"abstract":"","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"124 1","pages":"Pages 229-230"},"PeriodicalIF":6.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145719043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号